Jazz Pharmaceuticals Reports 16% Q2 Revenue Growth and Raises Full-Year Guidance

Key Facts

1Jazz Pharmaceuticals reported Q2 2026 revenue of $1.21B, a 16% year-over-year increase.

2The company raised its full-year guidance to a range of $4.60B to $4.75B.

3Ziihera received FDA approval for GEA treatment, marking a significant expansion into oncology.

Jazz Pharmaceuticals reported Q2 2026 revenue of $1.21B, representing a 16% year-over-year increase according to Seeking Alpha. The company raised its full-year guidance to a range of $4.60B to $4.75B, following the FDA approval of its drug Ziihera for the treatment of gastroesophageal adenocarcinoma.

JAZZ closed at $209.65 on October 14, 2026, as the company executes its strategy to diversify revenue streams away from oxybate reliance. The stock traded between a low of $209.36 and a high of $215.66 on October 14, 2026, supported by growth across its sleep medicine, epilepsy, and oncology portfolios.